BACE1 and Alzheimer disease: In this study using an anti-BACE1 monoclonal antibody, we showed that BACE1 levels become elevated in the brains of AlCl3-induced AD rats, which was subsequently reduced in the BSP-treated rats, suggesting that BSP could be a potential source for the development of BACE1 inhibitor drugs.